Dr. Jotin Marango and Yasmeen Rahimi have joined the healthcare research team at Roth Capital Partners.
Dr. Marango was appointed managing director and senior research analyst covering biotechnology and therapeutics. He joined Roth from H.C. Wainwright, where he covered hematology, oncology, and pulmonary therapeutics, with a particular focus on epigenetic and molecularly targeted therapies.
Dr. Rahimi was appointed a director and research analyst covering biotechnology and therapeutics, with particular interest in nonalcoholic fatty liver disease (NASH), metabolic and rare diseases. She also joined Roth from HCW.
In a statement, Jeff Martin, director of research, said Dr. Marango’s and Dr. Rahimi’s deep domain expertise in a broad spectrum of therapeutic areas will prove valuable in identifying biotechnology stocks with strong near-and long-term prospects.
Added Bryon Roth, CEO, “Coupled with the recent additions to our healthcare banking team, the academic and private sector backgrounds of Drs. Marango and Rahimi provide us with the additional resources and expertise to enhance our position as one of the leading investment banks for emerging healthcare companies and their investors.”
